Your browser doesn't support javascript.
loading
Efficacy of long-term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series.
Baba, Shimpei; Okanishi, Tohru; Homma, Yoichiro; Yoshida, Takeshi; Goto, Tomohide; Fukasawa, Tatsuya; Kobayashi, Satoru; Kamei, Atsushi; Fujii, Yuji; Hino-Fukuyo, Naomi; Yamada, Keitaro; Daida, Atsuro; Kawawaki, Hisashi; Hoshino, Hideki; Sejima, Hitoshi; Ishida, Yusuke; Okazaki, Tetsuya; Inui, Takehiko; Kanai, Sotaro; Motoi, Hirotaka; Itamura, Shinji; Nishimura, Mitsuyo; Enoki, Hideo; Fujimoto, Ayataka.
Affiliation
  • Baba S; Department of Child Neurology Comprehensive Epilepsy Center Seirei Hamamatsu General Hospital Hamamatsu Japan.
  • Okanishi T; Department of Child Neurology Comprehensive Epilepsy Center Seirei Hamamatsu General Hospital Hamamatsu Japan.
  • Homma Y; General Internal Medicine Seirei Hamamatsu General Hospital Hamamatsu Japan.
  • Yoshida T; Department of Pediatrics Kyoto University Graduate School of Medicine Kyoto Japan.
  • Goto T; Department of Neurology Kanagawa Children's Medical Center Yokohama Japan.
  • Fukasawa T; Department of Pediatrics Anjo Kosei Hospital Anjo Japan.
  • Kobayashi S; Department of Pediatrics Nagoya City West Medical Center Nagoya Japan.
  • Kamei A; Department of Pediatrics Iwate Medical University School of Medicine Shiwa Japan.
  • Fujii Y; Department of Pediatrics Hiroshima City Funairi Citizens Hospital Hiroshima Japan.
  • Hino-Fukuyo N; Department of Pediatrics Tohoku Medical and Pharmaceutical University Sendai Japan.
  • Yamada K; Department of Pediatric Neurology Aichi Developmental Disability Center Central Hospital Kasugai Japan.
  • Daida A; Department of Pediatrics St. Luke's International Hospital Tokyo Japan.
  • Kawawaki H; Department of Pediatric Neurology Osaka City General Hospital Osaka Japan.
  • Hoshino H; Department of Pediatrics Teikyo University School of Medicine Tokyo Japan.
  • Sejima H; Department of Pediatrics Matsue Red-Cross Hospital Matsue Japan.
  • Ishida Y; Department of Pediatrics Kobe University Graduate School of Medicine Kobe Japan.
  • Okazaki T; Division of Child Neurology Department of Brain and Neurosciences School of Medicine Tottori University Faculty of Medicine Yonago Japan.
  • Inui T; Department of Pediatric Neurology Miyagi Children's Hospital Miyagi Japan.
  • Kanai S; Department of Child Neurology Comprehensive Epilepsy Center Seirei Hamamatsu General Hospital Hamamatsu Japan.
  • Motoi H; Department of Child Neurology Comprehensive Epilepsy Center Seirei Hamamatsu General Hospital Hamamatsu Japan.
  • Itamura S; Department of Child Neurology Comprehensive Epilepsy Center Seirei Hamamatsu General Hospital Hamamatsu Japan.
  • Nishimura M; Division of Clinical Laboratory Seirei Hamamatsu General Hospital Hamamatsu Japan.
  • Enoki H; Department of Child Neurology Comprehensive Epilepsy Center Seirei Hamamatsu General Hospital Hamamatsu Japan.
  • Fujimoto A; Epilepsy and Surgery Comprehensive Epilepsy Center Seirei Hamamatsu General Hospital Hamamatsu Japan.
Epilepsia Open ; 6(2): 402-412, 2021 Jun.
Article in En | MEDLINE | ID: mdl-34095686
ABSTRACT

OBJECTIVES:

Long-term adrenocorticotropic therapy (LT-ACTH), which consisted of 2-4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT-ACTH for preventing WS relapse, as well as the prevalence of its adverse events.

METHODS:

This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT-ACTH. Clinical information of the patients and protocol of LT-ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan-Meier method.

RESULTS:

Clinical information of 16 children with WS was analyzed. The median age at LT-ACTH initiation was 14.5 months (range 7-68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT-ACTH regimens comprised a median of 16 days of daily injections (range 11-28 days) and 10 months of weekly injections (range 3-22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval 32.3%-80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported.

SIGNIFICANCE:

Our study firstly explored the efficacy of LT-ACTH for preventing WS relapse. LT-ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Spasms, Infantile Type of study: Guideline / Observational_studies / Risk_factors_studies Limits: Child / Humans Language: En Journal: Epilepsia Open Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Spasms, Infantile Type of study: Guideline / Observational_studies / Risk_factors_studies Limits: Child / Humans Language: En Journal: Epilepsia Open Year: 2021 Type: Article